Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1100
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 565–576 of 1,100 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Interventions
FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
Drug
Lead sponsor
Flare Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Not yet recruiting Not applicable Interventional

Isocaloric Navy-Bean Substitution in Adults With MASLD

NCT07730853
Site status not listed — check the official record
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
Site status not listed — check the official record
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional

Behavioral Therapy for Crohn's Disease

NCT06512597
Status at this site: Recruiting
View directory record Official record
Conditions
Crohn's Disease
Interventions
Primary Intervention for Combination Therapy - IBD Coping Strategies Program, Time and Attention Control - IBD Support Program
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593
Site status not listed — check the official record
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCB160058, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

NCT07277322
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Liver Metastases
Interventions
Dupilumab, Toripalimab
Drug
Lead sponsor
Dan Feng
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

NCT05099770
Site status not listed — check the official record
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT/ rilparencel), Sham Comparator
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
75
States / cities
Huntsville, Alabama • Tucson, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

NCT03220022
Site status not listed — check the official record
View directory record Official record
Conditions
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pacritinib in CMML

NCT06159491
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
Pacritinib, Azacitidine
Drug
Lead sponsor
Douglas Tremblay
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting No phase listed Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341
Status at this site: Recruiting
View directory record Official record
Conditions
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Liberant Thrombectomy System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

NCT05308264
Status at this site: Recruiting
View directory record Official record
Conditions
Low Risk Myelodysplastic Syndromes
Interventions
R906289 Monosodium (R289 Na)
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756
Site status not listed — check the official record
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 7:41 PM EDT

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.